John Goldberg
Chief Tech/Sci/R&D Officer en RAFAEL HOLDINGS, INC. .
Fortuna: 344 $ al 31/12/2023
Perfil
John M.
Goldberg is currently the Chief Medical Officer at Rafael Holdings, Inc. Prior to this, he was the Chief Medical Officer at Oncorus, Inc. from 2018 to 2023.
He also held the position of Senior Director-Medical at H3 Biomedicine, Inc. and Head-Clinical Development at Agenus, Inc. Dr. Goldberg received his undergraduate degree from The University of Chicago and his doctorate from the University of Massachusetts Medical School.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ONCORUS, INC.
0.01% | 31/03/2023 | 2 730 ( 0.01% ) | 344 $ | 31/12/2023 |
Cargos activos de John Goldberg
| Empresas | Cargo | Inicio |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 20/11/2023 |
Antiguos cargos conocidos de John Goldberg.
| Empresas | Cargo | Fin |
|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 30/06/2023 |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Formación de John Goldberg.
| The University of Chicago | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Empresas privadas | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Bolsa de valores
- Insiders
- John Goldberg
